Second Genome To Present Biomarker Data in Oncology at Keystone Symposium Company Identifies Microbiome-based Composite Biomarker Predictive of Response to Immune Checkpoint Inhibitor
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 19, 2021 /PRNewswire/ Second Genome, a leader in microbiome science, will present data today demonstrating the identification of a microbiome-based composite biomarker which can be used to predict response to immune checkpoint inhibitors. The data will be presented at the Keystone Symposium entitled Harnessing the Microbiome for Disease Prevention and Therapy being held from January 18-20. The oral presentation will be included in The Microbiome and Cancer session and is titled Microbiome-based biomarker predicts response to immune checkpoint inhibitor therapy in a melanoma meta-cohort independently of clinical features.